Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism
Status:
Unknown status
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
To optimize the Advagraf (tacrolimus once a day) initial daily dose used in de novo after
kidney transplantation in combination with MMF (or MPA) and corticosteroids (CS) regarding of
the genetic Cyp 450 3A5 polymorphism of the recipient.
The study of the tacrolimus through level (ng/ml) determines if the therapeutic level is
reached.